Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Preclinical Alzheimer's Disease Clear all
Recruiting Phase 3 Interventional Accepts healthy volunteers

Epidemiology and Biomarker Study in Alzheimer's Disease

NCT07142954
View directory record Official record
Conditions
Alzheimer Disease
Interventions
P-tau217 Test
Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 75 Years
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 1, 2026, 5:32 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT03131453
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CNP520 50mg, CNP520 15mg, Matching placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
1,145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
95
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 1, 2026, 5:32 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

NCT07142278
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
Interventions
DUVAX 200 µg, DUVAX 400 µg, Placebo (Adjuvant only)
Biological
Lead sponsor
Nuravax, Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 1, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Wandering Nerve: Gateway to Boost Alzheimer's Disease Related Cognitive Performance

NCT04908358
View directory record Official record
Conditions
Aging
Interventions
Active transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions, Sham transcutaneous vagus nerve stimulation respiratory-gated non-painful electrical stimulation of the auricle for 10 minute sessions
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 1, 2026, 5:32 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO

NCT02835716
View directory record Official record
Conditions
Alzheimer Disease
Interventions
roflumilast, ustekinumab
Drug · Biological
Lead sponsor
Millennium Magnetic Technologies, LLC
Industry
Eligibility
50 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Westport, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 13, 2016 · Synced Oct 1, 2026, 5:32 PM EDT
Recruiting Phase 3 Interventional

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

NCT07717411
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Trontinemab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Irvine, California • Santa Ana, California • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 1, 2026, 5:32 PM EDT
Recruiting No phase listed Observational

Depression and Driving

NCT05446805
View directory record Official record
Conditions
Depression, Drive
Interventions
F 18 AV-1451 (Flortaucipir), [11C]-Pittsburgh Compound B ([11C]PiB)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
150 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 1, 2026, 5:32 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

NCT02565511
View directory record Official record
Conditions
Alzheimers Disease
Interventions
CAD106 Immunotherapy, Placebo to CAD106, CNP520, Placebo to CNP520, Alum
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 1, 2026, 5:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PET Measures of CSF Clearance in Preclinical Alzheimer's Disease

NCT03663387
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
20 Years to 100 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 1, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease

NCT07794670
View directory record Official record
Conditions
Preclinical Alzheimer's Disease
Interventions
Obicetrapib 10 mg, Matching placebo tablets
Drug
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
55 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 1, 2026, 5:32 PM EDT
Completed No phase listed Observational

A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)

NCT04733989
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection
Other
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 1, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

Alzheimer's Prevention Through Exercise

NCT02000583
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aerobic Exercise, Standard of Care
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 1, 2026, 5:32 PM EDT
Active, not recruiting Phase 3 Interventional

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

NCT05026866
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
198
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 1, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

Alzheimer's Tau Platform: Master Protocol

NCT06957418
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
Interventions
AADvac1, Tau2
Drug
Lead sponsor
Paul S. Aisen
Other
Eligibility
50 Years to 80 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
San Francisco, California • Providence, Rhode Island • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 1, 2026, 5:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping

NCT04928976
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 1, 2026, 5:32 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension

NCT04937959
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Normal Cognition
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 1, 2026, 5:32 PM EDT
Recruiting Phase 1 Interventional

AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

NCT07158905
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease
Interventions
AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg, Placebo
Biological · Other
Lead sponsor
Institute for Molecular Medicine
Other
Eligibility
65 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Boca Raton, Florida • Miami Lakes, Florida • Stuart, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 1, 2026, 5:32 PM EDT
Recruiting No phase listed Observational

Imaging Biomarkers in Preclinical and Symptomatic AD

NCT04134923
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[11C] Pittsburgh Compound-B (PIB)
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 1, 2026, 5:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Atlas of Retinal Imaging in Alzheimer's Study

NCT03862222
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
Interventions
Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Actigraphy
Other · Diagnostic Test · Genetic
Lead sponsor
University of Rhode Island
Other
Eligibility
55 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
4
States / cities
Clearwater, Florida • St. Petersburg, Florida • Kingston, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 1, 2026, 5:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Predicting Pre-dementia

NCT07516119
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
Interventions
Not listed
Lead sponsor
Prevention Research Consortium Corp.
Other
Eligibility
55 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 1, 2026, 5:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study

NCT05350514
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes, Youth Onset
Interventions
PI-2620 tracer
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 1, 2026, 5:32 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease

NCT02045056
View directory record Official record
Conditions
Preclinical Alzheimer's Disease
Interventions
Gemfibrozil, Placebo
Drug
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
65 Years to 90 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 1, 2026, 5:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Financial Incentives and Recruitment to the APT Webstudy

NCT06033066
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Interventions
Financial Incentives, Message
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
50 Years and older
Enrollment
44,844 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Martinez, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 1, 2026, 5:32 PM EDT
Not listed No phase listed Observational

Evidence Amyloid Scan EEG Study

NCT03644043
View directory record Official record
Conditions
Alzheimer Disease, Dementia Frontal, Mild Cognitive Impairment
Interventions
EEG scan
Device
Lead sponsor
Metabolic Therapy Inc.
Other
Eligibility
60 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 1, 2026, 5:32 PM EDT